Result of Shareholder Analysis

Summary by AI BETAClose X

CRISM Therapeutics Corporation has announced the results of an independent shareholder register analysis as of June 30, 2026, identifying significant shareholders with interests of 3% or more in the company's ordinary share capital. The Miton UK Smaller Companies Fund holds the largest stake at 9.47%, followed by Mr. Andrew Webb with 9.22%, and Dr. Christopher McConville with 6.30%. Other substantial shareholders include Mr. Brian Murray (6.20%), Mr. David Lawton (5.07%), Zeus Dynamic Opportunities Fund (3.98%), Hobart Capital Markets LLP (3.57%), and Mr. John Rylands (3.02%).

Disclaimer*

CRISM Therapeutics Corporation
27 July 2026
 

27 July 2026

 

 

CRISM Therapeutics Corporation

("CRISM", "CRISM Therapeutics" or the "Company")

 

Results of Shareholder Analysis

CRISM Therapeutics Corporation (AIM: CRTX), a UK clinical-stage drug delivery company focused on the localised and sustained delivery of chemotherapy drugs, announces that following the completion of an independent third-party shareholder register analysis, that as at 30 June 2026, the Company is aware of the following significant shareholders, being those with an interest in 3% or more of the ordinary share capital of the Company ("Ordinary Shares"):

Shareholder

No. of Ordinary Shares

% interest in the ordinary share capital of the Company

Miton UK Smaller Companies Fund

7,500,000

9.47%

Mr Andrew Webb

7,297,190

9.22%

Dr Christopher McConville

4,992,033

6.30%

Mr Brian Murray

4,908,700

6.20%

Mr David Lawton

4,012,220

5.07%

Zeus Dynamic Opportunities Fund

3,150,000

3.98%

Hobart Capital Markets LLP

2,830,000

3.57%

Mr John Rylands

2,388,892

3.02%

 

-Ends-

 

Enquiries:

 

Company

Nomad and Broker

Financial PR

CRISM Therapeutics Corporation

S.P. Angel Corporate Finance LLP

Burson Buchanan

Andrew Webb, Executive Chairman

Chris McConville, CSO

David Hignell

Vadim Alexandre

Adam Cowl

Henry Harrison Topham

Jamie Hooper

CRISM@buchanancomms.co.uk

via Burson Buchanan

+44 (0) 20 3470 0470

+44 (0) 20 7466 5000

 

 

About CRISM Therapeutics Corporation

 

CRISM Therapeutics Corporation has developed an innovative drug delivery technology to improve the clinical performance of cancer treatments for solid tumours through the local delivery of chemotherapy drugs.

 

ChemoSeed, CRISM's lead product, can be implanted directly into the tumour or the resection margin following the removal of a tumour. This directs that therapeutic concentrations of chemotherapy drugs reach the deep-seated tumour tissue or cover the entire resection margin. In the case of treating glioblastoma, ChemoSeeds can be implanted during surgery thereby bypassing the blood brain barrier, which prevents other treatments from being able to reach the tumour and be effective.

 

For more information please visit: https://www.crismtherapeutics.com/

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 

Companies

Crism Therapeutics Corporation Ord Npv (CRTX)
UK 100
FTSE quotes by TradingView

Latest directors dealings

All directors dealings today